Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells

被引:10
|
作者
Sasu, Barbra J. [1 ]
Opiteck, Gregory J. [1 ]
Gopalakrishnan, Suhasni [1 ]
Kaimal, Vivek [1 ]
Furmanak, Tom [1 ]
Huang, David [1 ]
Goswami, Angshumala [1 ]
He, Ying [1 ]
Chen, Jiamin [1 ]
Nguyen, Anh [1 ]
Balakumaran, Arun [1 ]
Shah, Nirav N. [2 ]
Hamadani, Mehdi [2 ]
Bone, Kathleen M. [3 ]
Prashad, Sacha [1 ]
Bowen, Michael A. [1 ]
Pertel, Thomas [1 ]
Embree, Heather D. [1 ]
Gidwani, Shalini G. [1 ]
Chang, David [1 ]
Moore, Alison [1 ]
Leonard, Mark [1 ]
Amado, Rafael G. [1 ]
机构
[1] Allogene Therapeut, San Francisco, CA 94080 USA
[2] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
关键词
INVERSION; IMMUNOGLOBULIN; RECOMBINATION; IMMUNOTHERAPY; LYMPHOCYTES; INTEGRATION; ALIGNMENT; LYMPHOMA; THERAPY; SITES;
D O I
10.1016/j.ymthe.2022.12.004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A chromosome 14 inversion was found in a patient who devel-oped bone marrow aplasia following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene edits made with transcription activator-like effector nucleases (TALEN). TALEN editing sites were not involved at either breakpoint. Recombination signal sequences (RSSs) were found suggesting recombination-activating gene (RAG) -medi-ated activity. The inversion represented a dominant clone de-tected in the context of decreasing absolute CAR Tcell and overall lymphocyte counts. The inversion was not associated with clinical consequences and wasnot detected in the drug product administered to this patient or in any drug product used in this or other trials using the same manufacturing pro-cesses. Neither was the inversion detected in this patient at earlier time points or in any other patient enrolled in this or other trials treated with this or other product lots. This case il-lustrates that spontaneous, possibly RAG-mediated, recombi-nation events unrelated to gene editing can occur in adoptive cell therapy studies, emphasizes the need for ruling out off -target gene editing sites, and illustrates that other processes, such as spontaneous V(D)J recombination, can lead to chromo-somal alterations in infused cells independent of gene editing.
引用
收藏
页码:676 / 685
页数:10
相关论文
共 50 条
  • [1] Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
    Qasim, Waseem
    Zhan, Hong
    Samarasinghe, Sujith
    Adams, Stuart
    Amrolia, Persis
    Stafford, Sian
    Butler, Katie
    Rivat, Christine
    Wright, Gary
    Somana, Kathy
    Ghorashian, Sara
    Pinner, Danielle
    Ahsan, Gul
    Gilmour, Kimberly
    Lucchini, Giovanna
    Inglott, Sarah
    Mifsud, William
    Chiesa, Robert
    Peggs, Karl S.
    Chan, Lucas
    Farzaneh, Farzin
    Thrasher, Adrian J.
    Vora, Ajay
    Pule, Martin
    Veys, Paul
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (374)
  • [2] Automated generation of gene-edited CAR T cells at clinical scale
    Alzubi, Jamal
    Lock, Dominik
    Rhiel, Manuel
    Schmitz, Sabrina
    Wild, Stefan
    Mussolino, Claudio
    Hildenbeutel, Markus
    Brandes, Caroline
    Rositzka, Julia
    Lennartz, Simon
    Haas, Simone A.
    Chmielewski, Kay O.
    Schaser, Thomas
    Kaiser, Andrew
    Cathomen, Toni
    Cornu, Tatjana, I
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2021, 20 : 379 - 388
  • [3] Integration of a CD19 CAR into the. TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
    MacLeod, Daniel T.
    Antony, Jeyaraj
    Martin, Aaron J.
    Moser, Rachel J.
    Hekele, Armin
    Wetzel, Keith J.
    Brown, Audrey E.
    Triggiano, Melissa A.
    Hux, Jo Ann
    Pham, Christina D.
    Bartsevich, Victor V.
    Turner, Caitlin A.
    Lape, Janel
    Kirkland, Samantha
    Beard, Clayton W.
    Smith, Jeff
    Hirsch, Matthew L.
    Nicholson, Michael G.
    Jantz, Derek
    McCreedy, Bruce
    MOLECULAR THERAPY, 2017, 25 (04) : 949 - 961
  • [4] A Novel Booster Molecule Improves the Manufacture of TCR Gene-Edited Allogeneic CAR-T Therapies
    Shedlock, Devon
    Richter, Maximilian
    Cranert, Stacey
    Tong, Min
    Tan, Yening
    Codde, Rebecca
    Weiss, Leslie
    Coronella, Julia
    Ostertag, Eric
    MOLECULAR THERAPY, 2021, 29 (04) : 373 - 374
  • [5] Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent cells
    McEwan, Brigid
    Padalia, Zinkal
    Porras, Ashley
    Sagert, Jason
    Terrett, Jonathan A.
    Ho, Tony
    Kalaitzidis, Demetrios
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
    Zhang, Zhengchao
    Miao, Lele
    Ren, Zhijian
    Tang, Futian
    Li, Yumin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [7] Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa
    Gila, Fatemeh
    Alamdari-Palangi, Vahab
    Rafiee, Maedeh
    Jokar, Arezoo
    Ehtiaty, Sajad
    Dianatinasab, Aria
    Khatami, Seyyed Hossein
    Taheri-Anganeh, Mortaza
    Movahedpour, Ahmad
    Fallahi, Jafar
    JOURNAL OF APPLIED GENETICS, 2024, 65 (04) : 705 - 726
  • [8] Multi-step engineering of gene-edited CAR T cells using RNA lipid nanoparticles
    Clarke, Samuel
    Geczy, R.
    Balgi, A.
    Park, S.
    Zhao, R.
    Swaminathan, M.
    Tieu, R.
    Hoang, N.
    Webb, C.
    Watt, E.
    Wong, M.
    Fujisawa, M.
    Jain, N.
    Zhang, Angela
    Thomas, Anitha
    CANCER RESEARCH, 2023, 83 (07)
  • [9] First application of gene-edited 'universal' T cells for leukaemia
    Qasim, W.
    HUMAN GENE THERAPY, 2016, 27 (11) : A14 - A14
  • [10] Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare
    Sheridan, Cormac
    NATURE BIOTECHNOLOGY, 2022, 40 (01) : 5 - 8